Muscle & Brawn 2.0 is live! New Tools, Voice Reader, Compound Index, Features and more on the way. Want to explore what’s new → Click Here
Independent & reader-supported — every article medically reviewed

Peptides / GH and IGF

154 In the index

HGH Fragment 176-191 Frag

A small piece of growth hormone marketed for fat loss without growth hormone's other effects. The limited human trials that were done on it did not find it caused any more fat loss than a placebo.

Also known as AOD-9604, HGH frag, AOD 9604, RefChem:113278, Tyr-somatostatin (177-191), Somatostatin (177-191), Tyr-, Somatostatin (177-191), tyrosyl-, 7UP768IP4M, orb1910051, EX-A4625

Effects Lose fat
Routes Subcutaneous
Legal status Research chemical
WADA Banned at all times

Molecular Structure of C78H123N23O23S2

Drag to rotate · scroll to zoom

  • Carbon
  • Hydrogen
  • Nitrogen
  • Oxygen
  • Sulfur

PubChem has no 3D conformer for this molecule, so this is the flat structure.

Chemistry

Formula
C78H123N23O23S2
Molar mass
1815.1
CAS
221231-10-3
PubChem CID
71300630
IUPAC name
(2S)-2-[[2-[[(4R,7S,13S,16S,19S,22S,25R)-25-[[(2S)-5-amino-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylpentanoyl]amino]-3-methylbutanoyl]amino]-5-oxopentanoyl]amino]-22-(3-carbamimidamidopropyl)-13-(2-carboxyethyl)-7,19-bis(hydroxymethyl)-6,9,12,15,18,21,24-heptaoxo-16-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23-heptazacyclohexacosane-4-carbonyl]amino]acetyl]amino]-3-phenylpropanoic acid
InChIKey
GVIYUKXRXPXMQM-BPXGDYAESA-N

Reported dosing

User-reported

What has been reported in the literature and by users. This is a record of what is done, not a recommendation.

Typical dose 300-500 mcg/day
Reported range 250-750 mcg/day
Route Subcutaneous injection
Frequency Once or twice daily
Duration Ongoing/cyclical (unregulated use)

A modified fragment of human growth hormone marketed for fat loss without growth-promoting effects; not FDA-approved, and human efficacy data is limited.

Where this comes from Small early-phase clinical studies; user-reported/research-chemical vendor literature

There is no approved human dosing for this compound. The figures above are what users and vendors report, not what has been established as safe or effective. Treat them as a record of what is done, not as guidance.